Sorted By:

Relevance


Nearly 400 Medicines and Vaccines In Development to Fight Infectious Diseases

PhRMA  |  Press Release

Click here to read the full report.
https://www.phrma.org/press-release/nearly-400-medicines-and-vaccines-in-development-to-fight-infectious-diseases

Forced pharmaceutical localization fails to deliver

PhRMA  |  Blog Post

Published last week, Separating Fact from Fiction – How Localization Barriers Fail Where Positive Non-discriminatory Incentives Succeed, the report is a global analysis of localization barriers and the impact they have.
http://catalyst.phrma.org/forced-pharmaceutical-localization-fails-to-deliver

From Setbacks to Stepping Stones

PhRMA  |  Press Release

As detailed in the new “Medicines in Development for Alzheimer’s Disease” report, biopharmaceutical research companies are currently investigating or developing 93 new medicines for patients with Alzheimer’s and other dementias.
https://www.phrma.org/press-release/from-setbacks-to-stepping-stones

Why won’t the insurance industry tell the truth about medicine costs?

PhRMA  |  Blog Post

QuintilesIMS found net spending on medicines grew just 4.8 percent in 2016 – down from 8.9 percent in 2015.
http://catalyst.phrma.org/why-wont-the-insurance-industry-tell-the-truth-about-medicine-costs

Director – Public Affairs

PhRMA  |  PhRMA Career

The Director is responsible for: Working with the state public affairs team to develop and execute the communications, public affairs and media strategy for state advocacy priorities by closely tracking activities and work streams and providing media relations, communications counsel and support for PhRMA staff engaging with the media; Proactive outreach to reporters and other external audiences as well as handling responses to media inquiries;   Developing strong relationships with PhRMA colleagues, member companies, consultants and media, especially at the state level; Developing impactful messaging, advocacy and communications materials and reviewing the work of consultants including blog posts, op-eds, letters to the editor, press releases, talking points and presentations, among other materials; Collaborating with the State Advocacy and Advocacy & Strategic Alliances teams on their legislative, grassroots and third-party activities, including providing communications and messaging support; Aligning closely with other departments, including attending inter-departmental meetings, understanding advocacy goals/objectives, managing issues proactively and responding to requests promptly; Working with consultants in the development of social media content, press releases and statements, op-eds, pre-event briefings, and event reports.
https://www.phrma.org/careers/director-public-affairs

Medicare Monday: 3 reasons why repealing Part D’s noninterference clause is a bad idea

PhRMA  |  Blog Post

And a QuintilesIMS Institute report found that Part D plans receive an average discount of 35 percent from list prices across 12 widely used therapeutic areas.
http://catalyst.phrma.org/medicare-monday-3-reasons-why-repealing-part-ds-noninterference-clause-is-a-bad-idea

A new kind of Chart Pack

PhRMA  |  Blog Post

Whether sharing economic data in a meeting, discussing advances in research and development in the classroom, or simply trying to understand the many moving parts of the biopharmaceutical ecosystem, we hope that you find these reports to be a valuable and useful resource.
http://catalyst.phrma.org/a-new-kind-of-chart-pack

Medicare Monday: A closer look at Part B spending

PhRMA  |  Blog Post

That’s according to MedPAC and the Medicare Trustees report.
http://catalyst.phrma.org/medicare-monday-a-closer-look-at-part-b-spending

Failure to Prescribe the Indicated Treatment Is the Most Common Prescribing Quality Problem

Chartpack  |  From Our Network

Researchers report that failure to prescribe an indicated treatment is a far more common quality problem than is inappropriate medicine use.
http://chartpack.phrma.org/biophrma-chartpack/outcomes-and-savings/failure-to-prescribe-the-indicated-treatment-is-the-most-common-prescribing-quality-problem

Senior Director – Federal Advocacy

PhRMA  |  PhRMA Career

Requirements Bachelor’s degree in Political Science, Government Relations, Public Policy, or other related field of study;  5-7 years of direct experience working with or for the Congress and/or Federal Advocacy work; Understanding of procedures, protocols of standing committees regarding witnesses, testimony and Congressional activities, working knowledge of the Congressional process and ethics rules and regulations; Strong relationship building skills, integrity and reputation; easily builds a rapport and can persuade others Strategically anticipates potential future federal advocacy issues; Strong verbal and written communication skills; Demonstrated collaborator and team player.
https://www.phrma.org/careers/senior-director-federal-advocacy

Value Collaborative Videos

PhRMA  |  From PhRMA

Ubl, president and CEO, PhRMA Moderators: Drew Armstrong, health care reporter, Bloomberg Anna Edney, health regulation report, Bloomberg David Gura, anchor, television and radio, Bloomberg Precision Medicine Leaders Summit Spotlight: Paying for Personalized Value On August 21-24, the Precision Medicine Leaders Summit convened key thought leaders from government, academia, the biopharmaceutical industry and the payer and provider communities to discuss advancing the precision medicine field.
https://www.phrma.org/media/value-collaborative-videos

New First-of-Its-Kind Study Shows Growing Share of Medicine List Prices Going to Rebates and Supply Chain

PhRMA  |  Press Release

After accounting for discounts and rebates, the BRG report estimates that brand biopharmaceutical companies realized less than half (47 percent) of total U.S. spending on prescription drugs in 2015.
https://www.phrma.org/press-release/new-first-of-its-kind-study-shows-growing-share-of-medicine-list-prices-going-to-rebates-and-supply-chain

Special Edition Fact Check Friday: Why disclosing negotiated discounts and rebates won’t help patients

PhRMA  |  Blog Post

CBO reports that as a result, disclosure could ultimately increase the prices patients pay for their life-saving medicines.
http://catalyst.phrma.org/special-edition-fact-check-friday-why-disclosing-negotiated-discounts-and-rebates-wont-help-patients

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

ICYMI: Panel of doctors say new hep C treatments are cost effective: A recent Bloomberg story reports that new treatments for hepatitis C are cost-effective.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-july-17-2015

Innovative Medicines Help Turn HIV Infection into Chronic Disease

PhRMA  |  Press Release

Examples of potential innovations in the report include: • An antisense gene therapy that uses genetic material derived from HIV-1 itself to remove disease-causing aspects of the virus.
https://www.phrma.org/press-release/innovative-medicines-help-turn-hiv-infection-into-chronic-disease

The Next Big Debate in Health Care

Access Better Coverage  |  From Our Network

 Ever larger deductibles may dampen growth in spending but can also be asignificant burden for many family budgets and a barrier to care for the chronically ill.
http://www.accessbettercoverage.org/social-news/the-next-big-debate-in-health-care

Senior Manager of Application Support and Power BI

PhRMA  |  PhRMA Career

Professional Experience / Requirements  Bachelor’s degree or equivalent knowledge and experience; At least 5 years of experience in creating queries, reports, and dashboards using native reporting tools, SSRS, and Power BI; Experience with financial management and CRM systems; Excellent interpersonal, written and verbal communication skills; Ability to explain technical concepts to a non-technical audience; Ability to handle multiple responsibilities in a dynamic environment; Ability to work across departmental boundaries; Must be available as needed after hours and on weekends to facilitate planned maintenance as well as address emergency problems.
https://www.phrma.org

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Outdated rules in the following three key areas: government price reporting, Anti-Kickback Statute (AKS), and FDA rules on communications with payers, were reported by survey respondents as the greatest legal/regulatory barriers to advancing new approaches to paying for medicinesâ??
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Outdated rules in the following three key areas: government price reporting, Anti-Kickback Statute (AKS), and FDA rules on communications with payers, were reported by survey respondents as the greatest legal/regulatory barriers to advancing new approaches to paying for medicinesâ??
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

340B Spotlight: Audit findings show importance of increased oversight of 340B program

PhRMA  |  Blog Post

Without meaningful reform, the 340B program is expected to continue to grow at an alarming rate and further impact the market.
http://catalyst.phrma.org/340b-spotlight-audit-findings-show-importance-of-increased-oversight-of-340b-program

PhRMA Statement on Medicare Part D Premiums

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-medicare-part-d-premiums1

Alabama Clinical Trials Benefit Patients and the Economy

PhRMA  |  Press Release

“When I read the new report, I was struck not only by the quantity of trials our companies have conducted in the state, but also by the cutting-edge nature of much of the work,” he said. 
https://www.phrma.org/press-release/alabama-clinical-trials-benefit-patients-and-the-economy

340B Paradox: As the Uninsured Rate Drops, 340B Program Continues to Grow

PhRMA  |  Blog Post

(Available at: http://aspe.hhs.gov/health/reports/2015/MedicaidExpansion/ib_UncompensatedCare.pdf) [vi] Sales data from Apexus Update 2015 – 340B Coalition Winter Meeting; [vii] Vandervelde, Aaron.
http://catalyst.phrma.org/340b-paradox-as-the-uninsured-rate-drops-340b-program-continues-to-grow

Introduction

Chartpack  |  From Our Network

Data and information found in this publication were drawn from a wide range of sources, including government agency reports, peer-reviewed journals and the Pharmaceutical Research and Manufacturers of America’s (PhRMA) own research and analysis.
http://chartpack.phrma.org/biophrma-chartpack/introduction/introduction

340B Spotlight: Health Care Costs Rising from Increase in 340B Hospital Acquisitions of Physician Practices

PhRMA  |  Blog Post

Adding to a growing body of research on 340B hospital consolidation, the Community Oncology Alliance (COA) released a study last week that found much of the growth in the 340B program is concentrated in oncology medicines, which cost Medicare and beneficiaries more when administered through 340B hospitals than at independent physician practices.
http://catalyst.phrma.org/340b-spotlight-health-care-costs-rising-from-increase-in-340b-hospital-acquisitions-of-physician-practices

You have reviewed the first 400 results out of 1032. Each page contains 25 results. You're on page 16.

prev 13 14 15 16 17 18 next